為了提升心肌梗塞患者的組織修復(fù)能力和心臟功能，基于骨髓來源細(xì)胞通過旁分泌途徑起效的蛋白正日益成為一項(xiàng)核心治療方式。

收集了來自于急性心肌梗塞患者的骨髓來源細(xì)胞分泌的蛋白之后，研究者們使用生物信息學(xué)方法分析其分秘譜。經(jīng)過功能性篩選他們發(fā)現(xiàn)了一種由C19orf10基因（open reading frame on chromosome 19, 位于第19位染色質(zhì)的開放閱讀框）編碼的分泌蛋白，而這種蛋白能夠促進(jìn)心肌細(xì)胞的存活和血管新生。研究者們還發(fā)現(xiàn)，骨髓來源的單核細(xì)胞和巨噬細(xì)胞能內(nèi)源性產(chǎn)生這種蛋白并保護(hù)和修復(fù)心肌梗塞后的心臟，而且他們將此蛋白命名為髓源性生長因子（MYDGF，myeloid-derived growth factor）。

與野生型小鼠相比，Mydgf基因敲除的小鼠表現(xiàn)出更大的梗塞疤痕以及更嚴(yán)重的收縮功能紊亂。而恢復(fù)Mydfg基因表達(dá)能顯著緩解緊急梗塞之后產(chǎn)生的梗塞疤痕和心肌的收縮功能。此項(xiàng)研究首次報(bào)道了髓源性生長因子的生物學(xué)功能，并可能作為一種基于功能蛋白的修復(fù)缺血組織療法的典型范例。（生物谷世聯(lián)博研Bioexcellence）

本文系生物谷原創(chuàng)編譯整理，歡迎轉(zhuǎn)載！轉(zhuǎn)載請(qǐng)注明來源并附原文鏈接。謝謝！

生物谷推薦的英文摘要：

Nature Medicine doi:10.1038/nm.3778

Myeloid-derived growth factor (C19orf10) mediates cardiac repair following myocardial infarction

Mortimer Korf-Klingebiel, Marc R Reboll, Stefanie Klede, Torben Brod, Andreas Pich, Felix Polten, L Christian Napp, Johann Bauersachs, Arnold Ganser, Eva Brinkmann, Ines Reimann, Tibor Kempf, Hans W Niessen, Jacques Mizrahi, Hans-Joachim Sch?nfeld, Antonio Iglesias, Maria Bobadilla, Yong Wang & Kai C Wollert

Paracrine-acting proteins are emerging as a central mechanism by which bone marrow cell-based therapies improve tissue repair and heart function after myocardial infarction (MI). We carried out a bioinformatic secretome analysis in bone marrow cells from patients with acute MI to identify novel secreted proteins with therapeutic potential. Functional screens revealed a secreted protein encoded by an open reading frame on chromosome 19 (C19orf10) that promotes cardiac myocyte survival and angiogenesis. We show that bone marrow-derived monocytes and macrophages produce this protein endogenously to protect and repair the heart after MI, and we named it myeloid-derived growth factor (MYDGF). Whereas Mydgf-deficient mice develop larger infarct scars and more severe contractile dysfunction compared to wild-type mice, treatment with recombinant Mydgf reduces scar size and contractile dysfunction after MI. This study is the first to assign a biological function to MYDGF, and it may serve as a prototypical example for the development of protein-based therapies for ischemic tissue repair.